PE BIOSYSTEMS AND OXFORD GLYCOSCIENCES ANNOUNCE PROTEOMICS AGREEMENT

OGS to receive early access to new protein research system

Foster City, CA and Oxford, UK - September 18, 2000 - PE Biosystems Group (NYSE:PEB), a PE Corporation business now conducting business under the Applied Biosystems name, and Oxford GlycoSciences Plc (LSE: OGS) today announced they have signed an agreement for OGS to become an early access customer for Applied Biosystems' next-generation MALDI TOF/TOF mass spectrometer. This system is intended to enable higher throughput with enhanced informational content for researchers pursuing a better understanding of proteins and their role in the onset and treatment of disease.

The agreement provides that OGS should purchase MALDI TOF/TOF mass spectrometers, with the initial delivery of early access versions of the system beginning in the first half of calendar year 2001. In addition, Applied Biosystems would be able to incorporate any feedback on the system's performance into refinements of the system prior to commercial launch later in 2001. Additional terms of the agreement were not disclosed.

"This new generation of technology from Applied Biosystems could revolutionize peptide sequencing and, coupled with OGS's own advanced next generation bioinformatics software, could lead to significant new information on proteins' role in biological functions," said Professor Reid Townsend, Director of Proteomic Research at OGS. "This new information would be of particular value in the pursuit of new pharmaceuticals and diagnostics."

The MALDI TOF/TOF would offer researchers the potential to reach new levels of throughput as they conduct protein research (proteomics) on a larger scale. Enabling high-throughput analysis is critical for proteomics researchers due to the magnitude and complexity of proteins and their expression and interaction in living organisms.

"Our relationship with OGS and the new technology from our Framingham (MA) facility are both exciting developments in the evolution of protein research," said Michael W. Hunkapiller, Ph. D., president of Applied Biosystems. "OGS will be able to work with this system at an early date which should support them in advancing their 'industrial scale' proteomics capabilities."

Applied Biosystems is developing new tools to modernize proteomics much like new technology in the late '90s enhanced genomics. The group's Proteomics Research Center is leveraging Applied Biosystems' existing proteomics expertise and internal research capabilities while facilitating collaboration with complementary research and technology partners. The goal is to supply complete systems that decrease manual handling and increase the ability to obtain useful information.

The MALDI TOF/TOF utilizes Matrix Assisted Laser Desorption Ionization (MALDI) to make proteins into charged ions and Time of Flight/Time of Flight (TOF/TOF) analyzers to identify, sequence and characterize the ions. This system leverages Applied Biosystems' strength in MALDI-TOF mass spectrometry with the intention of increasing throughput and adding an integral second analyzer to provide additional sequence and characterization determination capability.

PE Corporation comprises two operating groups. The PE Biosystems Group, now conducting business under the Applied Biosystems name, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA and reported sales of $1.4 billion during fiscal 2000. The Celera Genomics Group (NYSE: CRA), headquartered in Rockville, Md., intends to become the definitive source of genomic and related medical information. Information about the Company, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800.762.6923.

OGS, is the world's leading proteomics company headquartered in Oxfordshire, UK, applying its proteomics technology in pharmaceutical research and development. OGS has proteomics collaborations with a number of major pharmaceutical companies, including programmes with Pfizer in Alzheimer's disease and atherosclerosis, with Merck in diabetes, and in respiratory disease with Bayer. OGS also has a proteomics programme with Pioneer Hi-Bred/DuPont. Furthermore, in a joint venture with the genomics company, Incyte Genomics Inc., OGS is building expression databases for licence to pharmaceutical companies, to which Astra Zeneca became the first subscriber in 1999.

OGS is also developing a therapeutic product, OGT 918, which is in late stage clinical trials for the treatment of glycolipid storage disease. In addition, the Company has drug discovery programmes in oncology, inflammation, and infectious disease.

For PE Biosystems: Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of PE Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) claims for patent infringement; (4) significant overseas operations; (5) future growth strategy; (6) earthquakes; and (7) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission.

For OGS: Some important facts that could cause actual results to vary significantly from management's expectations noted in these forward looking statements include government approvals, intellectual property positions and costs. OGT 918 is an investigational drug and has not received approval for marketing in any country.

Copyright © 2000. PE Corporation. All Rights Reserved.
Celera, Celera Genomics, PE Biosystems and Applied Biosystems are trademarks of PE Corporation.